Malays. Appl. Biol. (2012) 41(2): 45–49
ANTIMICROBIAL ACTIVITIES OF AQUEOUS LYSATE OF ACANTHAMOEBA SPP AGAINST SELECTED PATHOGENIC BACTERIA
NAKISAH, M.A.* and CHANDRIKA, K.
Department of Biological Sciences, Faculty of Science and Technology, Universiti Malaysia Terengganu, 21030 Kuala Terengganu, Terengganu, Malaysia.
*Email:
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
ABSTRACT
The increasing of infectious diseases and emerging of multi-drug resistant bacteria are worldwide problems that require a search for a new potential drug from various sources including free-living amoebae to overcome these problems. In this study, the aqueous lysates of two isolates of Acanthamoeba viz A. castellanii, a clinical isolate designated as IMR isolate, and Acanthamoeba sp., an environmental isolate designated as SW isolate were tested against two pathogenic bacteria, methicilin resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus. The anti-bacterial test was done using disc diffusion (Kirby Bauer) method to determine the minimum inhibition concentration (MIC) values of the lysates against the bacteria. Twofold dilution series of the Acanthamoeba lysates with concentrations ranging from 0.3 mg/mL to 2.4 mg/mL were used. The measurements of diameter of inhibition zone of the amoeba lysates against each bacterium were compared with the inhibition zone caused by a positive control (chloramphenicol) to analyse the effectiveness of the lysates as anti-bacterial agents. MRSA and S. aureus tested were slightly sensitive to both lysates of Acanthamoeba used in this study to suggest the potential of these lysates as bacterial agents. The data obtained were further confirmed by analysis of bacterial morphology under SEM.
ABSTRAK
Pertambahan penyakit berjangkit dan kemunculan bacteria rintan terhadap berbagai ubatan merupakan permasalahan di seluruh dunia yang memerlukan pencarian pelbagai sumber baharu sebagai ubatan termasuk ameba hidup bebas untuk mengatasi masalah ini. Dalam kajian ini, lisat akueus dari dua pemencilan Acanthamoeba iaitu A. castellanii, pemencilan klinikal ditetapkan sebagai isolat IMR dan Acanthamoeba sp., pemencilan dari sekitaran, ditetapkan sebagai isolat SW telah diuji terhadap dua bakteria pathogen yakni Staphylococcus aureus (MRSA) and Staphylococcus aureus. Ujian anti-bakteria dilakukan dengan menggunakan kaedah resapan cakra (Kirby Bauer) untuk menentukan nilai kepekatan perencatan minimum (MIC) lisat terhadap bakteria. Siri kepekatan duakali ganda lisat ameba dengan kepekatan berjulat 0.3mg/mL hingga 2.4 mg/mL digunakan. Pengukuran diameter kawasaan perencatan oleh lisat ameba ke atas setiap bakteria dibanding dengan kawasan perencatan oleh kawalan positif (chloramphenicol) untuk menganalisis keberkesanan lisat sebagai agen anti-bakteria. MRSA dan S. aureus yang diuji didapati sensitif terhadap kedua-dua lisat Acanthamoeba yang digunakan membuktikan keupayaannya sebagai agen anti-bakteria. Data yang diperolehi disahkan dengan melakukan analisis morfologi bakteria di bawah SEM.
Key words: Acanthamoeba lysates, SEM, MRSA, Staphylococcus aureus, MIC
REFERRENCES
Alekshun, M.N. & Levy, S.B. 2007. Molecular mechanisms of antibacterial multidrug resistance. Cell, 128: 1037-50.
Anderson, D.I. 2006. The biological cost of mutational antibiotic resistance: any practical conclusions. Current Opinion in Microbiology, 9: 461-465.
Jones, R.N. 1996. Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients. American Journal of Medicine, 100(6A): 3S-12S.
Keller, F., Hanke, W., Trissl, D. & Bakker-Grunwald, T. 1989. Pore-forming protein from Entamoeba histolytica forms voltage- and pH-controlled multi-state channels with properties similar to those of the barrel-stave aggregates. Biochima et Biophysica Acta 982(1): 89-93.
Kenneth, T. 2009. Bacterial Resistance to Antibiotics. www.textbookofbacteriology.net [Accessed on-line on 3 November, 2009]
Klugman, K.P. & Feldman, C. 1999. Penicillin- and cephalosporin-resistant Streptococcus pneumoniae. Emerging treatment for an emerging problem. Drugs. 58: 1-4.
Lynch, E.C., Rosenberg, I.M. & Gitler, C. 1982. An ion-channel forming protein produced by Entamoeba histolytica. EMBO Journal, 1: 801- 804.
Madigan, M. & Martinko, J. 2005. Brock Biology of Microorganisms (11 th ed.). Prentice Hall. Upper Saddle River, New Jersey, 992 pp. 49
Lorenzo-Morales, J., Ortega-Rivas, A., Foronda, P., Abreu-Acosta, N., Ballart, D., Martinez, E. & Valladares, B. 2005. RNA interference (RNAi) for silencing of extracellular serine proteases genes in Acanthamoeba: Molecular analysis and effect on pathogenecity. Molecular and Biochemical Parasitology, 68: 111-115.
Na, B.K., Kim, J.C. & Song, C.Y. 2001. Characterization and pathogenic role of proteinase from Acanthamoeba castellanii. Microbial pathogenesis 30: 39-48.
Nakisah, M.A., Iliana, F. & Houqe, M. 2005. Cytotoxic effect of Acanthamoeba lysates of T. lymphoblastic leukemic cell line (CEM-SS). In Proceedings of the 8 th Applied Biology Symposium. Medical Section Editors (Arshad et al., 2005). ISBN 983-41358-3-1.
Okuma, K., Iwakawa, K. & Turnidge, J.D. 2002. Dissemination of new methicilin resistant Staphylococcus aureus clones in community. Journal of Clinical Microbiology, 40: 4289- 4294.
Rosenberg, I., Bach, D., Loew, L.M. & Gitler, C. 1989. Isolation, characterization and partial purification of a transferable membrane channel (amoebapore) produced by Entamoeba histolytica, Molecular and Biochemical Parasitology, 33: 237-248.
Salton, M.J. & Kim, K.S. 1996. Structure, In: Baron’s Medical Microbiology, Baron et al. (Eds.), University of Texas Medical Branch. Witte, W. 2004. International dissemination of antibiotic resistant strains of bacterial pathogens. Infection, Genetics and Evolution, 4: 187-191.
World Health Organization (WHO). 2003. Critically important antibacterial agents for human medicine: categorization for the development of risk management strategies to contain antimicrobial resistance due to nonhuman use. Report of the second WHO Expert Meeting, Copenhagen, 29–31 May 2003.
